Evidence map›Paper›PMID 36879680›Full record

ArticleClinical case reports2023

Successful treatment with ivabradine in a β-blocker-refractory patient with acute decompensated heart failure with reduced ejection fraction.

Tomoko Inoue, Keiji Matsunaga, Waki Kobayashi, Tetsuo Minamino

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tomoko InoueDepartment of Cardiorenal and Cerebrovascular Medicine Faculty of Medicine Kagawa University Kagawa Japan.ORCID https://orcid.org/0000-0001-5504-9352
Keiji MatsunagaDepartment of Cardiorenal and Cerebrovascular Medicine Faculty of Medicine Kagawa University Kagawa Japan.
Waki KobayashiDepartment of Cardiorenal and Cerebrovascular Medicine Faculty of Medicine Kagawa University Kagawa Japan.
Tetsuo MinaminoDepartment of Cardiorenal and Cerebrovascular Medicine Faculty of Medicine Kagawa University Kagawa Japan.
Kagawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ivabradine is an established treatment for chronic heart failure with reduced ejection fraction (HFrEF); however, it is not used for acute heart failure treatment. Negative inotropic effects (NIE) often limit the up-titration of β-blockers. Contrarily, ivabradine has no NIE, and enables β-blockers usage for treating patients with acute decompensated HFrEF.

Indexed as

acute decompensated heart failurecancer therapy‐related cardiac dysfunctioninappropriate tachycardiaivabradineup‐titrationβ‐Blocker

Identifiers

PMID36879680
PMCPMC9984869
OpenAlexW4323049977

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.